Peptidomimetic-based antibody surrogate for HER2
Acta Pharmaceutica Sinica B
; (6): 2645-2654, 2021.
Artigo
em Inglês
| WPRIM (Pacífico Ocidental)
| ID: wpr-888877
Biblioteca responsável:
WPRO
ABSTRACT
Inhibition of human epidermal growth factor receptor 2 mediated cell signaling pathway is an important therapeutic strategy for HER2-positive cancers. Although monoclonal antibodies are currently used as marketed drugs, their large molecular weight, high cost of production and susceptibility to proteolysis could be a hurdle for long-term application. In this study, we reported a strategy for the development of artificial antibody based on
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Inglês
Revista:
Acta Pharmaceutica Sinica B
Ano de publicação:
2021
Tipo de documento:
Artigo